Procaps Group Sa Share Price (NASDAQ: PROC)

▲

-1.01

(-100%)

Last updated on February 3, 2025 at 12:00 am IST

$₹

The stock has been delisted from the stock exchange on 3 Feb 2025

Check the interactive Procaps Group Sa Stock chart to analyse performance

Procaps Group Sa Key Stats

Check Procaps Group Sa key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$1.01
Open	$0.95
Market Capitalization	$179.5M
Today's Volume	$659.0K
Revenue TTM	$414.1M
EBITDA	$57.1M
Earnings Per Share (EPS)	$0.51
PE Ratio	3.12
Profit Margin	12.61%
Quarterly Earnings Growth YOY	-0.64%
Return On Equity TTM	37.37%

Global Institutional Holdings in Procaps Group Sa

Name
Holdings %
Name
Holdings %
Exome Asset Management LLC
0.11%
Geode Capital Management, LLC
0.03%
Activest Wealth Management
0.01%

Analyst Recommendation on Procaps Group Sa Stock

Rating

Trend

Buy

75%Buy

25%Hold

0%Sell

Based on 8 Wall street analysts offering stock ratings for Procaps Group Sa(by analysts ranked 0 to 5 stars)

Procaps Group Sa Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

	FY19	Y/Y Change
Revenue	$324.8M	-
Net Income	$-17.0M	-
Net Profit Margin	-5.24%	-

	FY20	Y/Y Change
Revenue	$331.5M	↑ 2.06%
Net Income	$-10.4M	↓ 38.59%
Net Profit Margin	-3.15%	↑ 2.09%

	FY21	Y/Y Change
Revenue	$409.7M	↑ 23.61%
Net Income	$-100.9M	↑ 865.47%
Net Profit Margin	-24.62%	↓ 21.47%

	FY22	Y/Y Change
Revenue	$409.9M	↑ 0.04%
Net Income	$42.5M	↓ 142.18%
Net Profit Margin	10.38%	↑ 35.0%

	FY23	Y/Y Change
Revenue	$414.1M	↑ 1.02%
Net Income	$52.2M	↑ 22.72%
Net Profit Margin	12.61%	↑ 2.23%

Q2 FY22

Q3 FY22

Q4 FY22

Q1 FY23

Q2 FY23

Q3 FY23

	Q2 FY22	Q/Q Change
Revenue	$112.4M	↓ 11.16%
Net Income	$-6.9M	↓ 85.05%
Net Profit Margin	-6.15%	↑ 30.43%

	Q3 FY22	Q/Q Change
Revenue	$110.4M	↓ 1.79%
Net Income	$22.6M	↓ 426.35%
Net Profit Margin	20.45%	↑ 26.6%

	Q4 FY22	Q/Q Change
Revenue	$101.5M	↓ 8.09%
Net Income	$10.4M	↓ 53.79%
Net Profit Margin	10.28%	↓ 10.17%

	Q1 FY23	Q/Q Change
Revenue	$110.1M	↑ 8.47%
Net Income	$27.0M	↑ 158.34%
Net Profit Margin	24.49%	↑ 14.21%

	Q2 FY23	Q/Q Change
Revenue	$118.4M	↑ 7.59%
Net Income	$8.2M	↓ 69.6%
Net Profit Margin	6.92%	↓ 17.57%

	Q3 FY23	Q/Q Change
Revenue	$118.4M	↑ 0.0%
Net Income	$8.2M	↑ 0.0%
Net Profit Margin	6.92%	↑ 0.0%

FY19

FY20

FY21

FY22

FY23

	FY19	Y/Y Change
Profit	$182.5M	-

	FY20	Y/Y Change
Profit	$191.3M	↑ 4.83%

	FY21	Y/Y Change
Profit	$235.7M	↑ 23.21%

	FY22	Y/Y Change
Profit	$239.6M	↑ 1.64%

	FY23	Y/Y Change
Profit	$227.9M	↓ 4.87%

Q2 FY22

Q3 FY22

Q4 FY22

Q1 FY23

Q2 FY23

Q3 FY23

	Q2 FY22	Q/Q Change
Profit	$72.6M	↓ 4.0%

	Q3 FY22	Q/Q Change
Profit	$67.6M	↓ 6.99%

	Q4 FY22	Q/Q Change
Profit	$52.3M	↓ 22.65%

	Q1 FY23	Q/Q Change
Profit	$61.2M	↑ 17.1%

	Q2 FY23	Q/Q Change
Profit	$68.4M	↑ 11.79%

	Q3 FY23	Q/Q Change
Profit	$68.4M	↑ 0.0%

FY19

FY20

	FY19	Y/Y Change
Operating Cash Flow	$68.3M	-
Investing Cash Flow	$-12.1M	-
Financing Cash Flow	$-46.9M	-

	FY20	Y/Y Change
Operating Cash Flow	$70.9M	↑ 3.86%
Investing Cash Flow	$-17.1M	↑ 41.61%
Financing Cash Flow	$-40.5M	↓ 13.72%

Q2 FY22

Q3 FY22

Q4 FY22

Q1 FY23

Q2 FY23

	Q2 FY22	Q/Q Change
Operating Cash Flow	$10.0M	↓ 61.68%
Investing Cash Flow	$-8.9M	↑ 114.28%
Financing Cash Flow	$-26.0M	↓ 55.14%

	Q3 FY22	Q/Q Change
Operating Cash Flow	$5.8M	↓ 42.21%
Investing Cash Flow	$-7.5M	↓ 16.3%
Financing Cash Flow	$-5.4M	↓ 79.41%

	Q4 FY22	Q/Q Change
Operating Cash Flow	$-7.9M	↓ 238.01%
Investing Cash Flow	$-5.0M	↓ 32.62%
Financing Cash Flow	$27.9M	↓ 620.91%

	Q1 FY23	Q/Q Change
Operating Cash Flow	$20.4M	↓ 357.18%
Investing Cash Flow	$-5.0M	↑ 0.0%
Financing Cash Flow	$-25.0M	↓ 189.59%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$47.4M	↑ 131.98%
Investing Cash Flow	$-7.9M	↑ 56.65%
Financing Cash Flow	$-29.9M	↑ 19.44%

About Procaps Group Sa

Procaps Group S.A. develops, produces, and markets pharmaceutical solutions worldwide. The company formulates, manufactures, and markets branded prescription drugs in various therapeutic areas, including feminine care products, pain relief, skin care, digestive health, growth and development, cardiology, vision care, central nervous system, and respiratory. It also provides drugs for hospital use, such as antibiotic, blood clot, personal protective equipment, immunosuppressant, oncology, and analgesics products. In addition, the company offers over-the-counter (OTC) consumer healthcare products through a portfolio on approximately eight therapeutic areas, including gastrointestinal, skin care, cough and cold, analgesics, urological, vitamins, minerals, and supplements in the categories of antibiotics, anti-infective, anti-parasitic, cardiovascular, feminine care, cutaneous antimycotic, pain killers, gastro intestinal, hormonals, metabolic, endocrine, nervous system, ophthalmic, osteoarticular, respiratory, diet supplements, and vitamins and minerals. Further, it provides blood glucose meters, telemonitoring products, oral anti-diabetics products, cosmeceuticals, insulin delivery systems, and other diabetes solutions; and contract drug development and manufacturing services to third party pharmaceutical companies, specializing in soft gelatin capsule technologies. The company was founded in 1977 and is based in Luxembourg, Luxembourg.

Organization	Procaps Group Sa
Employees	5500
CEO	Mr. Jose Antonio Toledo Vieira
Industry	Miscellaneous

Key Management of Procaps Group Sa

Name	Title
Mr. Jose Antonio Toledo Vieira	Chief Executive Officer
Mr. Daniel Bernal	Interim Chief Financial Officer
Dr. Camilo Camacho	Chief Operations Officer
Ms. Melissa Angelini	Interim VP of Finance & Investor Relations Director
Ms. Marcela Carvajalino Pagano	Vice-President of Corporate & Legal Affairs
Mr. Luis Alberto Palacios Aragon	Vice-President of International Marketing and R&D
Mr. Mauricio Castaneda Caballero	Vice-President of Human Resources
Mr. Patricio Vargas Munoz	Chief Optimization and Rationalization Officer

Important FAQs about investing in PROC Stock from India :

What is Procaps Group Sa share price today?

Procaps Group Sa share price today is as on February 3, 2025 at 12:00 am IST at the close of the market. Procaps Group Sa share today touched a day high of {{1_rba_end}} and a low of {{1_rba_st}}.

What is the 52 week high and 52 week low for Procaps Group Sa share?

Procaps Group Sa share touched a 52 week high of {{rba_end}} and a 52 week low of {{rba_st}}. Procaps Group Sa stock price today i.e. February 3, 2025 at 12:00 am IST is closed at , lower by 100% versus the 52 week high.

How to invest in Procaps Group Sa Stock (PROC) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Procaps Group Sa on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Procaps Group Sa Shares .

What is the minimum amount required to buy Procaps Group Sa Stock (PROC) from India?

Indian investors can start investing in Procaps Group Sa (PROC) shares with as little as ₹88.3 or $1 (as of September 14, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹883.00 in Procaps Group Sa stock (as per the Rupee-Dollar exchange rate as on September 14, 2025). Learn more about fractional shares .

What are the returns that Procaps Group Sa has given to Indian investors in the last 5 years?

Procaps Group Sa stock has given 0.0% share price returns and 20.32% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?

Discover More

S&p Dividend Spdr
$140.72
-0.52%
T-rex 2x Long Microsoft Daily Target Etf
$34.17
+3.83%
Cp High Yield Trend Etf
$21.97
+0.05%
Ishares Intl Developed Small Cap Value Factor Etf
$45.03
-0.29%
Pharmacyte Biotech Inc
$1.04
+0.97%
Evgo Inc Cl A
$4.10
+4.06%
Crowdstrike Holdings, Inc.
$436.14
+0.64%
Ebang International Holdings Inc
$4.48
+4.43%
Heidmar Maritime Holdings Co
$1.10
-4.35%

Explore all